How to start a TRT telehealth business
Testosterone is a DEA Schedule III controlled substance, and that single fact reshapes the entire program. A platform that treats TRT like a GLP-1 refill is a compliance problem waiting to surface.
Key takeaways
- Testosterone is DEA Schedule III. That drives a synchronous initial visit, a narrower state map and a higher age floor.
- Baseline labs gate the first fill, and quarterly labs gate renewals. The gate has to be structural, not a reminder.
- Scheduled TRT is unavailable in many states. Enclomiphene, which is not controlled, covers all 50 plus D.C.
- Running both pathways captures traffic you have already paid for instead of declining it.
- Billing runs on twelve-week cycles to match the lab and visit cadence, not a monthly calendar.
Why TRT is a different business
Almost every operational assumption that works for weight management or hair loss fails here. Testosterone's controlled-substance status means a live visit before the first prescription rather than asynchronous review. Labs are not optional and not merely advisable, they gate the fill.
The state map is narrower, the age floor is higher, and renewals depend on current lab results rather than on the patient simply continuing to pay. If your platform cannot enforce those gates structurally, your operations team is enforcing them from memory, which is not a control.
The sequence, which is not negotiable
For a scheduled therapy the order is fixed: intake, then labs, then a live visit, then a prescription. Everything downstream depends on getting this right.
- Intake covering symptoms, medication history, cardiovascular and prostate history, and fertility intentions, which matter here in a way they do not elsewhere.
- Baseline labs including total and free testosterone plus a full panel, ordered in-flow with results returning into the patient record.
- A live video consultation with a clinician licensed where the patient is, going through the lab results together before any script exists.
- Fulfillment to a licensed compounding pharmacy for cypionate injection, cream or oral, matched to the state.
- Quarterly monitoring, with an annual panel in place of the fourth quarterly draw.
Two pathways, because one does not cover the country
Scheduled testosterone is available in a limited subset of states, commonly with an age floor around 25. A brand that only sells cypionate declines traffic it has already paid to acquire, in every state where it cannot serve.
Enclomiphene is not a controlled substance and is prescribable in all 50 states and D.C., typically from 18. It still carries lab requirements but can generally run on asynchronous review.
Routing the patient to whichever pathway their state and profile allow, rather than declining them, is the difference between a national brand and a regional one.
Renewal gates have to be enforced by the system
A renewal on a scheduled therapy should not process without current labs and a completed visit. If that gate lives in a checklist, it will eventually be missed, and it will be missed at scale.
Built into the platform, the refill simply cannot be approved without the prerequisites, the patient is prompted in the portal, and the case surfaces in a clinical queue. That is a control. A documented procedure is a hope.
Billing on the clinical calendar
Because the review cadence is quarterly, monthly billing creates a mismatch between what the patient is paying for and what the clinical relationship actually is.
Twelve-week cycles align the invoice with the lab and visit schedule. It also reduces the number of separate charge events, which in a category with elevated dispute sensitivity is worth having.
Labs in-flow, live visits where required, renewals that cannot skip the gate
PharmaBro orders labs inside the flow with results returning to the patient record, routes patients into a synchronous visit where the state and the medication require one, and blocks renewals that lack current results.
Both the scheduled testosterone and non-scheduled enclomiphene pathways are supported, with intake routing patients to whichever their state and profile allow.
Conclusion
TRT rewards operators who respect the sequence and punishes those who treat it as another subscription category.
Labs before the first fill, a live visit where the law requires it, renewals gated on current results, and a non-scheduled pathway for the states scheduled therapy cannot reach. Get those four right and the category is durable, high-retention and genuinely defensible.
Frequently asked questions
Can TRT be prescribed asynchronously?
Scheduled testosterone generally requires a synchronous visit before an initial prescription, alongside baseline labs. Non-scheduled pathways such as enclomiphene can typically run on asynchronous review with labs.
Is TRT available in every state?
No. Scheduled testosterone is available in a limited subset of states and commonly carries an age floor around 25. Enclomiphene, which is not a controlled substance, is prescribable in all 50 states and D.C.
What happens if a patient misses quarterly labs?
The renewal should not process. On a properly built platform the gate is structural: without current results and a completed visit the refill cannot be approved, the patient is prompted, and the case surfaces in a clinical queue.
Can I run TRT alongside a weight loss brand?
Yes, and most operators do because the audiences overlap. They are genuinely different clinical workflows, so they should run as separate programs rather than as one intake with a dropdown.
References
Priya RaghunathanHead of Compliance Operations
Handles LegitScript, HIPAA posture, MSO structuring and state coverage. Writes the parts of this blog that operators wish someone had told them before they signed.